DTG+2 NRTIs vs LPV/r+2 NRTIs (DAWNING): efficacy by baseline NRTI resistance and second-line NRTI use1

DAWNING is a non-inferiority study comparing DTG + 2 NRTIs with Lopinavir/r (LPV/r) + 2 NRTIs in HIV-1 infected adults failing first-line therapy of an NNRTI + 2 NRTIs.1

Post-hoc efficacy analyses were performed based on baseline NRTI resistance profile and NRTI use in the second-line background regimen (BR):
• Of 624 patients, 499 (80%) received <2 active NRTIs at baseline
• At Week 48, DTG demonstrated superior virological suppression vs LPV/r (84% vs 70%, respectively)
• Results were consistent regardless of the use of <2 or 2 fully active NRTIs in the BR. NRTI resistance was present in 90% of patients at baseline
• Response rates were high in the DTG group regardless of pre-existing resistance to an NRTI in the BR, including in patients using 3TC or FTC in the presence of M184V/I.1

This data supports the power of a dolutegravir-based-regimen in HIV-1 infected adults failing first-line therapy of an NNRTI + 2 NRTIs.1

  1. Brown D et al., Abstract 144, Presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, WA

PM-GB-DLT-WCNT-190001 - March 2019